These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29498768)

  • 21. A literature review of the psychological impact of genetic testing on breast cancer patients.
    Schlich-Bakker KJ; ten Kroode HF; Ausems MG
    Patient Educ Couns; 2006 Jul; 62(1):13-20. PubMed ID: 16242293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multigene Panel Testing for Hereditary Cancer and Genetic Counseling.
    Lee ES; Kim J; Han W
    Adv Exp Med Biol; 2021; 1187():455-471. PubMed ID: 33983594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters.
    Vos J; van Asperen CJ; Oosterwijk JC; Menko FH; Collee MJ; Gomez Garcia E; Tibben A
    Psychooncology; 2013 Apr; 22(4):902-10. PubMed ID: 22740372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dealing with the uncertainty of developing a cancer.
    Murphy AE
    Eur J Cancer Care (Engl); 1999 Dec; 8(4):233-7. PubMed ID: 10889621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The "Psychosocial Aspects in Hereditary Cancer" questionnaire in women attending breast cancer genetic clinics: Psychometric validation across French-, German- and Spanish-language versions.
    Brédart A; Anota A; Dick J; Cano A; De Pauw A; Kop JL; Aaronson NK; Bleiker EM; Brunet J; Devilee P; Stoppa-Lyonnet D; Schmutzler R; Dolbeault S
    Eur J Cancer Care (Engl); 2020 Jan; 29(1):e13173. PubMed ID: 31571365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with psychological distress during genetic counseling in high-risk women with breast cancer in Turkey.
    Anuk D; Tuncer SB; Özkan M; Yazıcı H
    Support Care Cancer; 2024 May; 32(6):359. PubMed ID: 38753118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.
    McCuaig JM; Tone AA; Maganti M; Romagnuolo T; Ricker N; Shuldiner J; Rodin G; Stockley T; Kim RH; Bernardini MQ
    Gynecol Oncol; 2019 Apr; 153(1):108-115. PubMed ID: 30638766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychological and health behaviour outcomes following multi-gene panel testing for hereditary breast and ovarian cancer risk: a mini-review of the literature.
    Carlsson L; Thain E; Gillies B; Metcalfe K
    Hered Cancer Clin Pract; 2022 Jun; 20(1):25. PubMed ID: 35733200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Knowledge and psychosocial impact of genetic counseling and multigene panel testing among individuals with ovarian cancer.
    Pozzar RA; Hong F; Xiong N; Stopfer JE; Nayak MM; Underhill-Blazey M
    Fam Cancer; 2022 Jan; 21(1):35-47. PubMed ID: 33751319
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
    Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
    Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development, technical validation, and clinical application of a multigene panel for hereditary gastrointestinal cancer and polyposis.
    Ricci MT; Volorio S; Signoroni S; Mariani P; Mariette F; Sardella D; Pensotti V; Vitellaro M
    Tumori; 2019 Aug; 105(4):338-352. PubMed ID: 31068090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study.
    Beri N; Patrick-Miller LJ; Egleston BL; Hall MJ; Domchek SM; Daly MB; Ganschow P; Grana G; Olopade OI; Fetzer D; Brandt A; Chambers R; Clark DF; Forman A; Gaber R; Gulden C; Horte J; Long J; Lucas T; Madaan S; Mattie K; McKenna D; Montgomery S; Nielsen S; Powers J; Rainey K; Rybak C; Savage M; Seelaus C; Stoll J; Stopfer JE; Yao XS; Bradbury AR
    Clin Genet; 2019 Feb; 95(2):293-301. PubMed ID: 30417332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Informing models of cancer genetics care in the era of multigene panel testing with patient-led recommendations.
    Underhill-Blazey M; Blonquist T; Chittenden A; Pozzar R; Nayak M; Lansang K; Hong F; Garber J; Stopfer JE
    J Genet Couns; 2021 Feb; 30(1):268-282. PubMed ID: 32851753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychological Impact of Learning CDKN2A Variant Status as a Genetic Research Result.
    Zhu X; Leof ER; Rabe KG; McCormick JB; Petersen GM; Radecki Breitkopf C
    Public Health Genomics; 2018; 21(3-4):154-163. PubMed ID: 30999302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic counseling does not fulfill the counselees' need for certainty in hereditary breast/ovarian cancer families: an explorative assessment.
    Vos J; Menko FH; Oosterwijk JC; van Asperen CJ; Stiggelbout AM; Tibben A
    Psychooncology; 2013 May; 22(5):1167-76. PubMed ID: 22777929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
    Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
    Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distress in unaffected individuals who decline, delay or remain ineligible for genetic testing for hereditary diseases: a systematic review.
    Heiniger L; Butow PN; Price MA; Charles M
    Psychooncology; 2013 Sep; 22(9):1930-45. PubMed ID: 23233440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect on perceived control and psychological distress of genetic knowledge in women with breast cancer receiving a BRCA1/2 test result.
    Brédart A; Kop JL; De Pauw A; Caron O; Fajac A; Noguès C; Stoppa-Lyonnet D; Dolbeault S
    Breast; 2017 Feb; 31():121-127. PubMed ID: 27837705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.